Compositions and methods for modulating cardiac conditions
Embodiments herein report methods and compositions for treating cardiac conditions. In certain embodiments, compositions and methods relate to reducing, inhibiting or treating a subject having or suspected of undergoing cardiac remodeling after a cardiac event. Other embodiments herein relate to compounds including naturally occurring and synthetic compositions of alpha-1 antitrypsin and fragments thereof.
1. A method for reducing cardiac remodeling in a subject in need thereof comprising:
administering to the subject having a cardiac condition a composition comprising alpha-1 antitrypsin (AAT), a fragment thereof, a fusion molecule thereof or a mutant thereof, wherein the composition reduces left ventricle end-diastolic diameters (LVEDD) and left ventricle end-systolic diameters (LVESD) in the subject compared to a control subject not receiving the composition; and
assessing LVEDD and LVESD in the subject within 24 hours of administering the composition to the subject.
2. The method of claim 1 , further comprising assessing LVEDD and LVESD at least one additional time following administering the composition to the subject.
3. A method for treating myocardial infarction in a subject in need thereof comprising:
identifying a subject having a myocardial infarction;
administering a therapeutically effective amount of a composition comprising one or more of AAT, a fusion molecule thereof, AAT mutant, one or more carboxyterminal peptides derived from AAT to the subject, wherein the composition reduces left ventricle end-diastolic diameters (LVEDD) and left ventricle end-systolic diameters (LVESD) in the subject; and
assessing LVEDD and LVESD in the subject within 24 hours of administering the composition to the subject.
4. The method of claim 3 , further comprising assessing LVEDD and LVESD at least one additional time following administering the composition to the subject.
5. A method for treating a subject suffering from a cardiac event comprising:
identifying a subject having a cardiac condition;
assessing the levels of caspase-1 activity in the subject;
administering a therapeutically effective amount of a composition comprising one or more of AAT, a fusion molecule thereof AAT mutant, one or more carboxyterminal peptides derived from AAT to the subject, wherein the composition reduces left ventricle end-diastolic diameters (LVEDD) and left ventricle end-systolic diameters (LVESD) in the subject; and
assessing LVEDD and LVESD in the subject within 24 hours of administering the composition to the subject.
6. The method of claim 5 , further comprising assessing LVEDD and LVESD at least one additional time following administering the composition to the subject.
7. The method of claim 1 , wherein the composition comprises naturally occurring AAT (SEQ ID NO:1).
8. The method of claim 1 , wherein the composition comprising alpha-1 antitrypsin (AAT) is a fusion molecule having AAT fused to human IgG or fragment of human IgG.
9. The method of claim 1 , wherein the composition comprises a composition of one or more carboxyterminal fragments of naturally occurring AAT.
10. The method of claim 1 , wherein the subject is suffering from acute myocardial infarction, myocardial ischemia, chronic systemic arterial and venous hypertension and pulmonary arterial and venous hypertension, congenital heart disease with and without intracardiac shunting, valvular heart disease, idiopathic dilated cardiomyopathy, infectious and non-infectious myocarditis, atrial or ventricular arrhythmias, cardioplegia, cardiac arrest, stress cardiomyopathy, septic cardiomyopathy or other event that damages heart muscle.
11. The method of claim 1 , wherein the composition reduces infarct size by at least 10% in the subject compared to the control subject not receiving the composition.
12. The method of claim 3 , wherein LVEDD and LVESD are reduced compared to a control subject not receiving the composition.
13. The method of claim 3 , wherein the therapeutically effective amount of the composition comprises a single intravenous infusion in the subject of AAT at a dose of about 20 mg/kg to about 150 mg/kg.
14. The method of claim 3 , further comprising analyzing blood samples from the subject for levels of active agents after administration.
15. The method of claim 5 , wherein the composition is administered to the subject within the first 48 hours of the cardiac event.
16. The method of claim 5 , wherein the composition is administered to the subject several days after the cardiac event.
17. The method of claim 5 , wherein the cardiac event comprises acute myocardial infarction, myocardial ischemia, chronic systemic arterial and venous hypertension and pulmonary arterial and venous hypertension, congenital heart disease with and without intracardiac shunting, valvular heart disease, idiopathic dilated cardiomyopathy, infectious and non-infectious myocarditis, atrial or ventricular arrhythmias, cardioplegia, cardiac arrest, stress cardiomyopathy, septic cardiomyopathy or other event that damages heart muscle.
18. The method of claim 5 , wherein the composition is administered to the subject daily for several days after the event.
19. The method of claim 5 , wherein the composition is administered within 24 hours and again several days after the cardiac event.
20. The method of claim 5 , wherein caspase-1 is measured before, during or after administration of the composition to the subject.